Page last updated: 2024-09-03

cimadronate and farnesol

cimadronate has been researched along with farnesol in 2 studies

Compound Research Comparison

Studies
(cimadronate)
Trials
(cimadronate)
Recent Studies (post-2010)
(cimadronate)
Studies
(farnesol)
Trials
(farnesol)
Recent Studies (post-2010) (farnesol)
105341,1619404

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Croucher, PI; Helfrich, MH; Rogers, MJ; Russell, RG; Shipman, CM1
Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K1

Other Studies

2 other study(ies) available for cimadronate and farnesol

ArticleYear
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Cancer research, 1998, Dec-01, Volume: 58, Issue:23

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Lovastatin; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Tumor Cells, Cultured

1998
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
    Cellular signalling, 2003, Volume: 15, Issue:7

    Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells

2003